Skip to content

Ayurvedic Formulation and Lifestyle Changes for mild to moderate Ulcerative Colitis: A Multi-Center Clinical Study

Multicenter double blind placebo (dummy) controlled randomized treat through trial of treatment with ayurvedic formulation and life style modification in patients with mild to moderate ulcerative colitis - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/088081
Enrollment
126
Registered
2025-06-02
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K519- Ulcerative colitis, unspecified

Interventions

None listed

Sponsors

Indian Council of Medical Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Confirmed cases of mild to moderate endoscopically active ulcerative colitis (UC endoscopic index of severity or UCEIS more than 1) and disease extent beyond rectum and simple clinical colitis activity score between 3-9 2 Patients on stable dose of mesalamine for past 4 weeks 3 Patients on stable dose of azathioprine or 6 mercaptopurine for past 3 months 4 Patients on stable doses of topical therapy for past 2 weeks 5 willing to participate

Exclusion criteria

Exclusion criteria: 1 history of oral steroids in the past 4 weeks 2 History of or oral antibiotics within past 2 weeks 3 Patients with severe disease activity 4 Patients with fulminant colitis requiring hospitalization 5 Patients who have had surgery 6 Patients with Crohns colitis 7 Patients with concomitant GI infection 8 Patients with comorbidities like acute myocardial infarction chronic kidney disease or chronic liver disease 9 Patients with significant hepatic renal endocrine respiratory neurologic or cardiovascular diseases will also be excluded 10 Pregnant lactating females 11 Patients with allergy to Ayurvedic formulations 12 Patients with Diabetes 13 Patients with severe co-morbidities

Design outcomes

Primary

MeasureTime frame
Clinical remission defined as SCCAI less than equal to 2Timepoint: 8 weeks and 48 weeks

Secondary

MeasureTime frame
Clinical Response Timepoint: at 8 and 48 weeks;Endoscopic response and remissionTimepoint: 8 and 48 weeks;Deep RemissionTimepoint: 8 and 48 weeks;Quality of LifeTimepoint: 8 and 48 weeks;Adverse eventsTimepoint: 8 and 48 weeks

Countries

India

Contacts

Public ContactDr Gautam Sharma

AIIMS Delhi

drgautamsharma12@gmail.com9811388311

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026